As competition heats up, Novo Nordisk’s share price declines

Original Article by Liesl Peyper | Moneyweb | 24 October 2024

Novo Nordisk's share price dropped 19% amidst growing competition from Eli Lilly in the diabetes and weight-loss drug market.

Novo Nordisk’s share price dropped 19% amidst growing competition from Eli Lilly in the diabetes and weight-loss drug market.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here